ABSTRACT
Objective To investigate the problems during using, standard and quality management of the POCT glucose meters in hospital, to analyze the solutions, and to provide reference data for improving the test level of POCT in hospital.Methods The amount, brand and application of portable glucose meters in the hospital were obtained by 3 rounds of surveillance from May to July in 2013.All of those glucose meters were taken part in external quality assessment of Clinical Laboratory Center of National Health and Family Planning Commission.The test results of those glucose meters were compared with that of automatic biochemical analyzer, the comparison results were then analyzed.Results The POCT glucose meters possessed 5 brands in our hospital, and the amount and type of glucose meters in some clinical departments were often changed.When 4 brands which were detected as quality control samples by ministry of health, the accuracy of detection results of 3 concentration of brand Ⅲ were substandard, the CV% of two levels were 11.9%and 10.1%respectively, the remaining 3 brands were in line with the requirements.The qualified percentages of 3 times of comparison were 85.0%, 92.0%and 97.4%.Conclusions The hospital should select the brand of portable glucose meters reasonably, correct use of glucose meters, and it is very necessary to build indoor and interstitial quality evaluation system, at the same time, suggesting the hospital to establish the POCT quality management team, to carry out the instrument comparison periodically, so to guarantee the accurate, reliable results of POCT in hospital.
ABSTRACT
Objective To discuss the effect of the concentration of dihydrotestostemne(DHT)in prostatic tissue treating by 5a-reductase inhibitors.Methods One hundred and twenty-one pros-tatic samples were selected:group A1(18 patients treating by epristeride for 1 month),group A2(22patients treating by epristeride for 3 months),group B1(23 patients treating by finasteride for 1 month),group B2(21 patients treating by finasteride for 3 months),group C(25 patients non-treating by 5α-reductase inhibitors),group D(12 samples of prostate from body).The concentration of DHT was measured by radio-immunity,Results The concentration of DHT in prostate declined after treating by epristeride 1 month and 3 months(66.21%and 70.60%,P＜0.05).The decline of the concentration of DHT in prostate after treating by epristeride 1 month was larger than 3 months(P＜0.05).The concentration of DHT in prostate declined after treating by finasteride 1 month and 3 months.There Was no signiificant difference of the concentration of DHT in prostate after treating by finasteride 1 month and 3 months.Conclusions The concentration of DHT in prostate can be declined after treating by epristeride and finasteride.The decline of the concentration of DHT is consistent aftertrealring by epristeride.The decline of the concentration of DHT is considerable between epristeride and finasteride.
ABSTRACT
ObjectiveTo investigate the finasteride application during the off-cycle of intermittent androgen blockade (IAB) in patients with advanced prostate cancer treated with IAB.MethodsEighty-seven patients with advanced prostate cancer were divided into two groups: forty-nine patients received IAB (group A), and thirty-eight patients underwent IAB and finasteride during the off-cycle of IAB (group B). The time of treatment cycle and the time to disease progression were compared between the two groups. ResultsThe patients in group A completed 89 treatment cycles and the mean cycle length was (12.8±5.4) months [treatment time and non-treatment time were (6.6±3.5) months and (7.1±4.8) months, respectively]. The patients in group B completed 85 cycles and the mean cycle length was (15.3±5.9) months [treatment time and non-treatment time were (6.9±3.2) months and (9.2v±3.9) months, respectively]. There was a significant difference between group A and B in the mean cycle length and the non-treatment time (P=0.0428,P=0.03).The 3-year progression rate was ( 34.8±3.5 )% in group A and ( 28.4±2.7)% in groups B ( P=0.035). ConclusionsThe application of finasteride during the off-cycle of IAB in patients with advanced prostate cancer treated with intermittent androgen blockade (IAB) can delay progression of advanced prostate cancer.